Beijing Hotgen Biotech Co., Ltd. (SSE Code: 688068) ("Hotgen") is a biotechnology company in Beijing, focusing on in-vitro diagnosis (IVD) and antibody medicines. Founded in 2005, Hotgen takes up a mission of “Developing biotechnology, Benefiting human health”, formulating 8 IVD technology platforms for research and manufacturing, covering over 30 countries. The company became the first IVD company listed on China’s STAR Board in 2019, and achieved a sales of CNY3.6 billion in 2022.Hotgen develops over 100 diagnostic parameters involving cardiac, liver diseases, inflammation, drug abuse, and etc, which can be categorized into 4 sections, i.e. mono-test chemiluminescence platform, up-converting phosphorus technology (UPT) platform, and colloidal gold rapid tests and enzyme-linked immunoassay tests.